- organizations:Ocular Therapeutix
Pipeline
First patients enrolled in Ocular Therapeutix phase 3 wet AMD study
New SOL-R trial intends to provide real-world evidence supporting the potential for axitinib intravitreal implant redosing every 6 months.
Pipeline
Ocular Therapeutix releases positive NPDR phase 1 data, plans for wet AMD repeat dosing study
Updates follow company’s decision to cut 13% of workforce in order to focus on the clinical development of axitinib intravitreal implant.
Business
Ocular Therapeutix to cut 13% of workforce
Company cites new initiative to prioritize clinical development of its axitinib intravitreal implant for wet AMD, currently in a phase 3 trial.
Business
Ocular Therapeutix announces executive chairman as new CEO
Effective immediately, Pravin U. Dugel, MD, will also take over as president.
Pipeline
FDA amends SPA for Ocular Therapeutix phase 3 wet AMD trial
Modification allows the company to accelerate the enrollment process for the SOL trial.
Pipeline
Ocular Therapeutix initiates first pivotal trial of implant for wet AMD
OTX-TKI offers the potential for long-term durability with fewer injections.
Research
Enrollment completed for Ocular Therapeutix's HELIOS trial in DR
OTX-TKI has the potential to offer long-term durability and a reduced need for frequent, invasive injections.
Pipeline
Ocular Therapeutix releases 12-month topline data from phase 1 wet AMD trial
Efficacy of OTX-TKI could potentially extend beyond three to four months with a single injection.
Pipeline